This is a competitive renewal application for the Paul Calabresi Career Development Award for Clinical Oncology (K12) funded and initiated in January 2010. The objective of the program is to provide a framework for the development of clinical and translational physician-scientists at the Albert Einstein College of Medicine. This ha been achieved through a coordinated program of mentoring, an established innovative series of formal courses, and research projects with an interdisciplinary, collaborative design. The program, its leadership and participants are integrated within the established research programs of the NCI-designated Albert Einstein Cancer Center (AECC) and Einstein's Institute for Clinical and Translational Research (ICTR); the latter focused on the training and mentoring of young clinical investigators. The Einstein Calabresi Program selects highly qualified clinical and translational investigators, primarily MDs but including some PhDs, that are committed to developing careers in patient-oriented clinical and translational research. The training focus is on cancer therapeutics. A formal curriculum has been developed in conjunction with Einstein's ICTR (funded in part by a CTSA grant) featuring an MS degree in Clinical Research Methods and a new course on Clinical Trial Development in the Era of Personalized Cancer Medicine along with individualized instruction based on the background and needs of each Scholar. The leadership of the program brings together senior Einstein faculty with strong backgrounds in cancer therapeutics research, postgraduate training in the clinical oncology disciplines, and clinical research methods. The Principal Investigators are Dr. Roman Perez-Soler, Professor of Medicine, Deputy Director of the AECC, and co-director of AECC's Experimental Therapeutics Program and Dr. Mark Einstein, Professor and Vice-Chair for Research in the Department of Obstetrics & Gynecology. Both PI's have an established track-record of translational research in cancer therapeutics as well as mentoring junior clinical investigators. The Educational Coordinator, Dr. Paul Marantz, is Associate Dean for Clinical Research Education and Associate Director of Einstein's ICTR. He is an innovator in the development of educational programs in clinical research methods for physicians and is co-PI of Einstein's CTSA. Novel initiatives are planned including training for mentors and processes for the external evaluation of the program. An Advisory Committee of AECC's senior faculty leaders provide oversight in the selection and ongoing evaluation of the progress of Calabresi Scholars and the impact of the program. The leadership is assisted by an External Advisory Committee with members experienced in directing Calabresi programs at other institutions. Over the first four years of funding, fourteen Scholars were recruited to the program from medical-, pediatrics-, radiation- and gynecological- oncology. Two Scholars were PhDs, the rest MDs or MD/PhDs. Nine Scholars will have completed the program by the end of the current period of support, all pursuing successful careers at major academic centers, six at Einstein.

Public Health Relevance

The objective of this program is to train clinical and translational physician-scientists to develop new treatments for cancer at the Albert Einstein College of Medicine. This will be achieved through a coordinated program of mentoring, innovative didactic courses, and the performance of research projects with an interdisciplinary collaborative design.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA132783-08
Application #
9040101
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Damico, Mark W
Project Start
2009-04-01
Project End
2020-03-31
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
8
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine, Inc
Department
Type
DUNS #
079783367
City
Bronx
State
NY
Country
United States
Zip Code
10461
Anampa, Jesus; Chen, Alice; Wright, John et al. (2018) Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer. Clin Breast Cancer 18:e135-e142
Fulcher, Cory D; Haigentz Jr, Missak; Ow, Thomas J et al. (2018) AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma. Head Neck 40:676-686
Nadaradjane, Celine; Yang, Chia-Ping Huang; Rodriguez-Gabin, Alicia et al. (2018) Improved Dose-Response Relationship of (+)-Discodermolide-Taxol Hybrid Congeners. J Nat Prod 81:607-615
Kabarriti, Rafi; Quinn, Thomas J; Ewart, Michelle R et al. (2018) Neoadjuvant radiation therapy for the management of myoepithelial carcinoma of the upper extremity. Int J Cancer 142:854-862
Ohri, Nitin; Bodner, William R; Kabarriti, Rafi et al. (2018) Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 102:709-715
Darbinyan, Karine; Shastri, Aditi; Budhathoki, Anjali et al. (2017) Hispanic ethnicity is associated with younger age at presentation but worse survival in acute myeloid leukemia. Blood Adv 1:2120-2123
Samaraweera, Leleesha; Adomako, Alfred; Rodriguez-Gabin, Alicia et al. (2017) A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC. Sci Rep 7:1900
Nandikolla, Amara G; Venugopal, Sangeetha; Anampa, Jesus (2017) Breast cancer in patients with Li-Fraumeni syndrome - a case-series study and review of literature. Breast Cancer (Dove Med Press) 9:207-215
Jimenez, Lizandra; Lim, Jihyeon; Burd, Berta et al. (2017) miR-375 Regulates Invasion-Related Proteins Vimentin and L-Plastin. Am J Pathol 187:1523-1536
Ohri, Nitin; Kabarriti, Rafi; Bodner, William R et al. (2017) Continuous Activity Monitoring During Concurrent Chemoradiotherapy. Int J Radiat Oncol Biol Phys 97:1061-1065

Showing the most recent 10 out of 76 publications